MediciNova,Inc. Logo

MediciNova,Inc.

Developing small-molecule drugs for neurology, respiratory, and liver diseases.

4875 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
米国カリフォルニア州ラ・ホイヤ、スウィート300、エグゼクティブ・スクエア4275
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for serious diseases with unmet medical needs. The company's primary development efforts are concentrated on neurology, respiratory, and liver diseases. Its pipeline includes candidates such as MN-221, targeting respiratory conditions like acute exacerbations of asthma and COPD, and MN-001 for fibrotic diseases, including liver fibrosis (NASH) and idiopathic pulmonary fibrosis (IPF).

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for MediciNova,Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-12 07:44
Regulatory News Service
確認書
Japanese 8.4 KB
2025-09-12 07:43
Interim Report
半期報告書
Japanese 386.0 KB
2025-06-25 03:32
Regulatory News Service
臨時報告書
Japanese 16.6 KB
2025-06-10 06:52
Regulatory News Service
内部統制報告書
Japanese 51.3 KB
2025-06-10 06:51
Regulatory News Service
確認書
Japanese 12.9 KB
2025-06-10 06:50
Annual Report
有価証券報告書
Japanese 3.0 MB
2024-09-11 04:32
Regulatory News Service
確認書
Japanese 13.0 KB
2024-09-11 04:28
Interim Report
半期報告書
Japanese 436.9 KB
2024-06-17 09:06
Regulatory News Service
臨時報告書
Japanese 15.4 KB
2024-06-13 05:03
Regulatory News Service
確認書
Japanese 13.1 KB
2024-06-13 05:02
Quarterly Report
四半期報告書
Japanese 424.9 KB
2024-06-10 09:48
Regulatory News Service
内部統制報告書
Japanese 51.4 KB
2024-06-10 09:46
Annual Report
有価証券報告書
Japanese 3.3 MB
2024-06-10 09:46
Regulatory News Service
確認書
Japanese 12.9 KB
2023-12-12 06:01
Regulatory News Service
確認書
Japanese 13.1 KB

Automate Your Workflow. Get a real-time feed of all MediciNova,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for MediciNova,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan 4575
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan 7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan 4880
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland CLN
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark CESSA

Talk to a Data Expert

Have a question? We'll get back to you promptly.